Saving, changing and repairing lives
Research in the Department focuses on chronic diseases affecting the CNS, Immune, Respiratory, Cardiovascular and Dental systems, including in the newborn and children. Improved envenomation management in adults and children represent a major focus of our research led by AVRU and CCTC in Australia and Papua New Guinea (PNG) within large international collaborations including with WHO. We have consistently demonstrated success in progressing our laboratory findings through different stages of drug development. Clinically, the department is involved in a number of drug trials/ developments: MOR103, a monoclonal antibody against GMCSF, developed by Morphosys (Munich) based on a concept from the Dept, is now in phase II/III for indications such as RA and MS with GSK in Europe. AVRU have just completed a phase II trial in Port Moresby (PNG) with a new antivenom against the taipan, a major deadly snake in PNG and Australia. LHRC will conduct two clinical trials in Australia in 2017/2018 with two new anticalins in asthma and eye diseases in collaboration with Pieris, an emerging German/US biotech. LHRC will also conduct a clinical trial to study the effects of reinforced flu vaccination in patients with recurrent severe asthma attacks. LHRC also participates in a study run by the Royal Melbourne Hospital on the efficacy of the anti-IgE antibody omalizumab in patients with systemic mastocytosis.
Dr Jon Mangum has created a biotech (Incisive) to develop treatment and diagnosis of a devastating dental problem in children, molar hypomineralisation, also known as chalky teeth. Prof. A. Stewart (LHRC, TTRI) has led the discovery of a new pathway in TGFβ signalling and is developing a new class of drugs to treat treatment steroid-resistant asthma patients. Prof N. Saunders leads a company that provides sailing as a means to rehabilitate spinal cord injury paraplegic or tetraplegic patients, in addition to his research on blood brain barrier in embryos and infants and spinal cord injury in developing mammals. TTRI is seeking to transform drug screening processes through organ-on-a-chip technology and incorporating mechanopharmacology.
Prof. D. Hoyer, with his colleague Prof. W. Charman, Dean of Pharmacy and Head of the Monash Institute of Pharmaceutical Sciences, have conceptualised and launched Project Mercury, a historic 80M AUD joint venture between Monash University and University of Melbourne, with the support of the Victorian Government, to create the first Australian Academic Drug Development Incubator established as BioCurate PTY Ltd under the chair of the Hon. J. Brumby, former Premier of Victoria.
Keywords: ACROMEGALY; ANTIVENOMS; ANXIETY; ASTHMA; AUSTRALIA; BIOMEDICAL; BIPOLAR DISORDERS; CHRONIC DISEASE; COPD; DEPRESSION; DISEASE; EPILEPSY; GASTROENTEROPANCREATIC; HYPERTENSION; INTERSTITIAL PULMONARY FIBROSIS; IRRITABLE BOWEL SYNDROME; LUNG CANCER; LUNG HEALTH RESEARCH; MECHANOPHARMACOLOGY; MICROFLUIDICS; MIGRAINE; NEUROLOGICAL DISORDERS; ORGAN ON A CHIP; PANIC; PATIENT COHORTS; PHARMACOLOGY; PHASE 1 AND 2 CLINICAL TRIALS; POST-TRAUMATIC STRESS DISORDER; PULMONARTY HYPERTENSION; SCHIZOPHRENIA; SLEEP DISORDERS; SNAKE BITES; THERAPEUTIC TECHNOLOGIES; THERAPEUTICS; TRANSLATIONAL RESEARCH; TUMOURS; VENOMS; WHO
Document Type: Research Article
Publication date: February 1, 2017
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites